Novartis
Encouraging Performance of Cardiovascular Drug Vindicates Novartis’ $9.7 Billion Buyout Deal
2020-09-06
Novartis’ Kesimpta Notches FDA Approval as Targeted B-cell Therapy for Patients with Relapsing MS
2020-08-23
Novartis Enters $75 Million Collaboration with Sangamo for its Zinc Finger Gene Editing Technology
2020-08-01
Novartis Reveals Positive Ofatumumab Data for Treating Relapsing Forms of Multiple sclerosis
2020-06-07
Novartis’ Kisqali Shows Promising Results in Advanced Breast Cancer Patients with Liver Metastases
2020-05-28